GAVI negotiates HPV vaccine prices for developing countries
This article was originally published in Scrip
The GAVI Alliance has announced it is to fund vaccines against the human papillomavirus (HPV) and negotiations with the companies that market vaccines, GlaxoSmithKline and Merck & Co, are underway, said a GAVI spokesperson. The public-private vaccination initiative says it must secure a "sustainable price" from manufacturers. It is unclear what this price might be, but will likely be below $5 per dose.
You may also be interested in...
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.
To maintain high prices and avoid access restrictions, companies marketing advanced therapies will have to show payers that their products save money elsewhere in the healthcare system.